You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
健康元(600380.SH):託珠單抗注射液新增兩個適應症獲批
格隆匯 05-07 17:07

格隆匯5月7日丨健康元(600380.SH)公佈,近日,公司重要控股子公司麗珠醫藥集團股份有限公司(以下簡稱:麗珠集團)控股子公司珠海市麗珠單抗生物技術有限公司(以下簡稱:麗珠單抗,公司直接和間接持有的麗珠單抗的權益為55.90%)收到國家藥品監督管理局核准簽發的《藥品補充申請批准通知書》(通知書編號:2023B01996、2023B01997),批准託珠單抗注射液增加用於CAR-T細胞引起的嚴重或危及生命的細胞因子釋放綜合徵(CRS)及用於2歲或2歲以上兒童的活動性全身型幼年特發性關節炎(sJIA)兩個適應症。

託珠單抗注射液本次新增兩個適應症,擴展了本品的應用範圍,進一步提高了本品的市場競爭力。產品的經營情況因受市場環境變化等因素的影響,具有不確定性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account